Neos Therapeutics Inc. | Mutual Funds
Mutual Funds that own Neos Therapeutics Inc.
FTIF SICAV - Franklin Biotechnology Discovery Fund
1,023,600
3.45%
0
0.25%
06/30/2018
Vanguard Total Stock Market Index Fund
615,637
2.08%
0
0%
07/31/2018
Franklin Biotechnology Discovery Fund
614,800
2.06%
0
0.24%
03/31/2018
Franklin Small Cap Growth Fund
608,738
2.04%
0
0.12%
03/31/2018
iShares Russell 2000 ETF
579,555
1.95%
-309
0.01%
09/06/2018
Russell US Small Cap Equity Fund
406,153
1.37%
172,434
0.11%
04/30/2018
iShares Nasdaq Biotechnology ETF
334,343
1.12%
-4,368
0.02%
09/06/2018
Vanguard Extended Market Index Fund
284,638
0.96%
0
0%
07/31/2018
iShares Russell 2000 Growth ETF
258,924
0.87%
0
0.01%
09/06/2018
Fidelity Spartan Extended Market Index Fund
97,688
0.33%
0
0%
07/31/2018
| Address |
2940 North Highway 360
Grand Prairie Texas 75050
United States
|
|
Employees
|
- |
| Website |
http://www.neostx.com |
| Updated |
07/08/2019 |
| Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. |
